Barbara Stefanska

Prof. Barbara Stefanska

Faculty of Land and Food Systems, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MBMegan Beetch
Megan Beetch
SHSadaf Harandi‐Zadeh
Sadaf Harandi‐Zadeh
KSKate Shen
Kate Shen
Katarzyna Lubecka-GajewskaKatarzyna Lubecka-Gajewska
Katarzyna Lubecka-Gajewska
DKDavid D. Kitts
David D. Kitts
BSBarbara Stefanska
Barbara Stefanska
Chronic diseases account for over 60% of all deaths worldwide according to the World Health Organization reports. Majority of cases are triggered by environmental exposures that lead to aberrant changes in the epigenome, specifically, the DNA methylation patterns. These changes result in altered expression of gene networks and activity of signalling pathways. Dietary antioxidants, including catechins, flavonoids, anthocyanins, stilbenes and carotenoids, demonstrate benefits in the prevention and/or support of therapy in chronic diseases. This review provides a comprehensive discussion of potential epigenetic mechanisms of antioxidant compounds in reversing altered patterns of DNA methylation in chronic disease. Antioxidants remodel the DNA methylation patterns through multiple mechanisms, including regulation of epigenetic enzymes and chromatin remodelling complexes. These effects can further contribute to antioxidant properties of the compounds. On the other hand, decrease in oxidative stress itself can impact DNA methylation delivering additional link between antioxidant mechanisms and epigenetic effects of the compounds.Linked Articles: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

12 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBMegan Beetch
Megan Beetch
SHSadaf Harandi-Zadeh
Sadaf Harandi-Zadeh
TYTony Yang
Tony Yang
CBCayla Boycott
Cayla Boycott
YCYihang Chen
Yihang Chen
Sulma I. MohammedSulma I. Mohammed
Sulma I. Mohammed
Triple-negative breast cancer (TNBC) is a subtype of breast cancer unresponsive to traditional receptor-targeted treatments, leading to a disproportionate number of deaths. Invasive breast cancer is believed to evolve from non-invasive ductal carcinoma in situ (DCIS). Detection of triple-negative DCIS (TN-DCIS) is challenging, therefore strategies to study molecular events governing progression of pre-invasive TN-DCIS to invasive TNBC are needed. Here, we study a canine TN-DCIS progression and investigate the DNA methylation landscape of normal breast tissue, atypical ductal hyperplasia (ADH), DCIS and invasive breast cancer. We report hypo- and hypermethylation of genes within functional categories related to cancer such as transcriptional regulation, apoptosis, signal transduction, and cell migration. DNA methylation changes associated with cancer-related genes become more pronounced at invasive breast cancer stage. Importantly, we identify invasive-only and DCIS-specific DNA methylation alterations that could potentially determine which lesions progress to invasive cancer and which could remain as pre-invasive DCIS. Changes in DNA methylation during TN-DCIS progression in this canine model correspond with gene expression patterns in human breast tissues. This study provides evidence for utilizing methylation status of gene candidates to define late-stage (DCIS and invasive), invasive stage only or DCIS stage only of TN-DCIS progression.

1 December 2021 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
MBMegan Beetch
Megan Beetch
CBCayla Boycott
Cayla Boycott
SHSadaf Harandi-Zadeh
Sadaf Harandi-Zadeh
TYTony Yang
Tony Yang
BMBenjamin J.E. Martin
Benjamin J.E. Martin
BSBarbara Stefanska
Barbara Stefanska

29 February 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LKLucinda Kurzava Kendall
Lucinda Kurzava Kendall
YMYuexi Ma
Yuexi Ma
TYTony Yang
Tony Yang
Katarzyna Lubecka-GajewskaKatarzyna Lubecka-Gajewska
Katarzyna Lubecka-Gajewska
BSBarbara Stefanska
Barbara Stefanska
The crosstalk between oncogenic signaling pathways plays a crucial role in driving cancer development. We previously demonstrated that dietary polyphenols, specifically resveratrol (RSV) and other stilbenoids, epigenetically target oncogenes for silencing via DNA hypermethylation in breast cancer. In the present study, we identify signal transduction regulators among RSV-hypermethylated targets and investigate the functional role of RSV-mediated DNA hypermethylation in the regulation of Hedgehog and Wnt signaling. Non-invasive ER-positive MCF-7 and highly invasive triple-negative MCF10CA1a human breast cancer cell lines were used as experimental models. Upon 9-day exposure to 15 µM RSV, pyrosequencing and qRT-PCR were performed to assess DNA methylation and expression of GLI2 and WNT4, which are upstream regulators of the Hedgehog and Wnt pathways, respectively. Our results showed that RSV led to a DNA methylation increase within GLI2 and WNT4 enhancers, which was accompanied by decreases in gene expression. Consistently, we observed the downregulation of genes downstream of the Hedgehog and Wnt signaling, including common targets shared by both pathways, CCND1 and CYR61. Further analysis using chromatin immunoprecipitation identified increased H3K27 trimethylation and decreased H3K9 and H3K27 acetylation, along with abolishing OCT1 transcription factor binding. Those changes indicate a transcriptionally silent chromatin state at GLI2 and WNT4 enhancers. The inhibition of the Wnt signal transduction was confirmed using a phospho-antibody array that demonstrated suppression of positive and stimulation of negative Wnt regulators. In conclusion, our results provide scientific evidence for dietary polyphenols as epigenetics-modulating agents that act to re-methylate and silence oncogenes, reducing the oncogenic signal transduction. Targeting such an action could be an effective strategy in breast cancer prevention and/or adjuvant therapy.

20 July 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
MBMegan Beetch
Megan Beetch
Katarzyna Lubecka-GajewskaKatarzyna Lubecka-Gajewska
Katarzyna Lubecka-Gajewska
KSKate Shen
Kate Shen
KFKirsty Flower
Kirsty Flower
SHSadaf Harandi‐Zadeh
Sadaf Harandi‐Zadeh
BSBarbara Stefanska
Barbara Stefanska

3 June 2018 in Epigenetics
Verified
Journal Article
Open access
Katarzyna Lubecka-GajewskaKatarzyna Lubecka-Gajewska
Katarzyna Lubecka-Gajewska
KFKirsty Flower
Kirsty Flower
MBMegan Beetch
Megan Beetch
JQJay Qiu
Jay Qiu
LKLucinda Kurzava
Lucinda Kurzava
BSBarbara Stefanska
Barbara Stefanska
Late onset of clinical symptoms in hepatocellular carcinoma (HCC) results in late diagnosis and poor disease outcome. Approximately 85% of individuals with HCC have underlying liver cirrhosis. However, not all cirrhotic patients develop cancer. Reliable tools that would distinguish cirrhotic patients who will develop cancer from those who will not are urgently needed. We used the Illumina HumanMethylation450 BeadChip microarray to test whether white blood cell DNA, an easily accessible source of DNA, exhibits site-specific changes in DNA methylation in blood of diagnosed HCC patients (post-diagnostic, 24 cases, 24 controls) and in prospectively collected blood specimens of HCC patients who were cancer-free at blood collection (pre-diagnostic, 21 cases, 21 controls). Out of 22 differentially methylated loci selected for validation by pyrosequencing, 19 loci with neighbouring CpG sites (probes) were confirmed in the pre-diagnostic study group and subjected to verification in a prospective cirrhotic cohort (13 cases, 23 controls). We established for the first time 9 probes that could distinguish HBV-negative cirrhotic patients who subsequently developed HCC from those who stayed cancer-free. These probes were identified within regulatory regions of BARD1, MAGEB3, BRUNOL5, FXYD6, TET1, TSPAN5, DPPA5, KIAA1210, and LSP1. Methylation levels within DPPA5, KIAA1210, and LSP1 were higher in prospective samples from HCC cases vs. cirrhotic controls. The remaining probes were hypomethylated in cases compared with controls. Using blood as a minimally invasive material and pyrosequencing as a straightforward quantitative method, the established probes have potential to be developed into a routine clinical test after validation in larger cohorts.